Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer

By Ganesan Prasanth   Piha-Paul Sarina   Naing Aung   Falchook Gerald   Wheler Jennifer   Fu Siqing   Hong David   Kurzrock Razelle   Janku Filip   Laday Shell   Bedikian Agop   Kies Merrill   Wolff Robert   Tsimberidou Apostolia  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 279-286

Springer Publishing Company

Access to resources Recommend Favorite

Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer

By Michael Michael   Gibbs Peter   Smith Robert   Godwood Alex   Oliver Stuart   Tebbutt Niall  

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 253-261

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors

By Kalmadi S.   Davis M.   Dowlati A.   O’Keefe S.   Cline-Burkhardt M.   Pelley R.   Borden E.   Dreicer R.   Bukowski R.   Mekhail T.  

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 211-216

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer

By Okamoto Isamu   Miyazaki Masaki   Morinaga Ryotaro   Kaneda Hiroyasu   Ueda Shinya   Hasegawa Yoshikazu   Satoh Taroh   Kawada Akira   Fukuoka Masahiro   Fukino Koichi   Tanigawa Takahiko   Nakagawa Kazuhiko  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 844-853

Springer Publishing Company

Access to resources Recommend Favorite

A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer

By Moulder Stacy   Dhillon Navneet   Ng Chaan   Hong David   Wheler Jennifer   Naing Aung   Tse Susan   La Paglia Amy   Dorr Robert   Hersh Evan   Boytim Michelle   Kurzrock Razelle  

Investigational New Drugs, Vol. 28, Iss. 5, 2010-10 ,pp. : 634-640

Springer Publishing Company

Access to resources Recommend Favorite